LTR Pharma (ASX:LTP) said over 1,000 prescriptions of Spontan had been issued in Australia under the Therapeutic Goods Administration (TGA) Special Access Scheme, according to a Wednesday Australian bourse filing.
Under the scheme, clinicians can request access to Spontan where approved treatments are unsuitable, ineffective, or unavailable.
De-identified data collection from the prescriptions under the scheme is ongoing.
Its shares rose 2% in recent trading on Wednesday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.